Consequently, the present findings will provide valuable insights into the pharmacological and physiological mechanisms of SGLT2 inhibitor therapy, to develop effective strategies for managing obesity in patients with diabetes. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.